62
Views
13
CrossRef citations to date
0
Altmetric
Articles

Development of amine-containing polymeric particles

Pages 1233-1244 | Published online: 02 Apr 2012
 

Abstract

The objective of this study was to synthesize and characterize particles as a drug-delivery platform for gliomas, a highly advanced and invasive stage of brain tumor with poor prognosis. Poly(aminoethyl methacrylate-co-methyl methacrylate) particles were prepared by suspension polymerization and poly(aminoethyl methacrylate-co-poly(ethylene glycol) methacrylate) particles were prepared by emulsion (w/o) polymerization. Amine groups of the particles were complexed with tetrachloroplatinate to form a cisplatin-like molecule. Particles were characterized with respect to size, ζ-potential, amine content, loading efficiency and drug release. Poly(aminoethyl methacrylate-co-methyl methacrylate) particles had diameters of below 10 μm, whereas the poly(aminoethyl methacrylate-co-poly(ethylene glycol) methacrylate) particles had diameters of approx. 1 μm. Poly(aminoethyl methacrylate-co-poly(ethylene glycol) methacrylate) particles had a more positive ζ-potential as compared to poly(aminoethyl methacrylate-co-methyl methacrylate) particles, although the amino-group content of both particles was almost equivalent. The net positive charge on the particles decreased after complexation with tetrachloroplatinate for both types of particles. Both particles had very high platinum-loading efficiency (>85%) and showed slow release of platinum over time. Particles had relatively low cytotoxicity (LC50 > 100 μg/ml) and demonstrated a high degree of association with cells. Complexation with poly(aminoethyl methacrylate-co-methyl methacrylate) particles significantly reduced the toxicity of platinum. The poly(aminoethyl methacrylate-co-poly(ethylene glycol) methacrylate) particles have potential for being an effective drug-delivery platform and continued investigation is warranted.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.